Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia

Międzybrodzki, Ryszard; Hoyle, Naomi; Zhvaniya, Fikria; Łusiak-Szelachowska, Marzanna; Weber‐Dąbrowska, Beata; Łobocka, Małgorzata; Borysowski, Jan; Alavidze, Zemphira; Kutter, Elizabeth; Górski, Andrzej; Gogokhia, Lasha

doi:10.1007/978-3-319-40598-8_31-1

Cited by 24 publications

(32 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…149,150 Activities include production of phages and application of phage therapy, based on a large collection of selected phages and pathogenic bacterial strains that are tested for their susceptibility to their phages. 151 In addition, HIIET has treated over 2000 patients with bacterial infections resistant to antibiotic treatment with an overall success rate from 30% to 90%, depending on the pathogen involved and clinical setting. This is still one of the best sets of solidly documented phage therapy research and clinical data available today directly related to the spread of antibiotic resistance.…”

Section: Phage Therapy Research and Applications In Central And Westementioning

confidence: 99%

A century of bacteriophage research and applications: impacts on biotechnology, health, ecology and the economy!

Vandamme

Mortelmans

2018

J of Chemical Tech & Biotech

View full text Add to dashboard Cite

About a century ago, bacteriophages or phages – viruses that infect bacteria – were discovered and reported in the scientific literature. This review aims at a comprehensive survey of bacteriophage discovery, research and applications since the 1920s, and its impact on molecular biology, biotechnology, health, ecology and the economy. Phage therapy has been proven a valuable asset to deal with pathogenic bacterial infections since the early 1920s, and has been practiced ever since, especially in the former Soviet Union and in Eastern Europe. The Western world remained sceptical and resorted to the widespread use of antibiotics since the 1940s. Now that antibiotic resistance among pathogenic bacteria has spread alarmingly and few really novel antibiotic compounds are in the pipeline, renewed attention is being directed to the use of phages as antibacterial agents in medicine. Because of this renewed interest in phage therapy in the Western world, novel applications with phages are being pursued in the human health, environmental and the agri‐food sectors. This review will focus on (1) the history of early phage use and its successes and problems, (2) the study of phages as important tools in the development of molecular biology and biotechnology, (3) current developments in phage research including the use of phage endolysins for use in antibacterial treatment, (4) phage production systems including undesirable phage contamination of industrial fermentation processes based on bacteria, (5) recent applications in phage therapy and in phage‐based control, and (6) the roles of phages in nature and in the human gut. © 2018 Society of Chemical Industry

show abstract

Section: Phage Therapy Research and Applications In Central And Westementioning

confidence: 99%

A century of bacteriophage research and applications: impacts on biotechnology, health, ecology and the economy!

Vandamme

Mortelmans

2018

J of Chemical Tech & Biotech

View full text Add to dashboard Cite

show abstract

“…The use of the viruses of bacteria, bacteriophages (phages), as therapeutic agents to treat bacterial infections began 20 years before the first clinical use of an antibiotic drug, but the introduction of broad-spectrum antibiotics in the 1940s rapidly eclipsed and displaced the development of phage therapeutics in much of the world. Phage therapy continued to be developed with ongoing use in the Soviet Union and Eastern Europe that continues to the present in Poland, Russia, and Georgia [1][2][3]. However, until the rising global dissemination of multidrug-resistant (MDR) bacterial infections [4], earnest interest in clinical application was not evident in Western Europe and the Americas, nor in much of the rest of the world.…”

Section: Introductionmentioning

confidence: 99%

Bacteriophage Therapy: Developments and Directions

Nikolich

Filippov

2020

Antibiotics

View full text Add to dashboard Cite

In an era of proliferating multidrug resistant bacterial infections that are exhausting the capacity of existing chemical antibiotics and in which the development of new antibiotics is significantly rarer, Western medicine must seek additional therapeutic options that can be employed to treat these infections. Among the potential antibacterial solutions are bacteriophage therapeutics, which possess very different properties from broad spectrum antibiotics that are currently the standard of care, and which can be used in combination with them and often provide synergies. In this review we summarize the state of the development of bacteriophage therapeutics and discuss potential paths to the implementation of phage therapies in contemporary medicine, focused on fixed phage cocktail therapeutics since these are likely to be the first bacteriophage products licensed for broad use in Western countries.

show abstract

“…Previously published reports of therapy safety also suggesting its efficacy in human clinical practice, many reports showing its efficacy in animal models of acute bacterial infections and especially recent reports of dramatic results achieved in patients with serious infections using intravenous (IV) phage therapy [2,3] seem to mitigate skepticism and contribute to the recent rise of interest in the therapy. The safety of phage therapy has also been suggested in patients up to 7 years after completion of PT [4]. We proposed that 'our model of phage therapy applied as experimental treatment should continue to be implemented by other medical centers' and suggested that 'IV PT using purified phage preparations should be seriously considered' [5].…”

Section: Introduction: Current Developments In Phage Therapymentioning

confidence: 99%